Literature DB >> 18220914

Umbilical cord blood: a unique source of pluripotent stem cells for regenerative medicine.

David T Harris1, Ian Rogers.   

Abstract

It is estimated that almost 1 in 3 individuals in the United States might benefit from regenerative medicine therapy. Unfortunately, embryonic stem (ES) cell therapies are currently limited by ethical, political, biological and regulatory hurdles. Thus, for the foreseeable future, the march of regenerative medicine to the clinic will depend upon the development of non-ES cell therapies. Current sources of non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood. Each of these types of stem cells has already begun to be utilized to treat a variety of diseases. This review will show that cord blood (CB) contains multiple populations of ES-like and other pluripotential stem cells, capable of giving rise to hematopoietic, epithelial, endothelial, and neural tissues both in vitro and in vivo. Cumulatively, the identification and isolation of these populations of pluripotent stem cells within cord blood represents a scientific breakthrough that could potentially impact every field of medicine, via their use in regenerative medicine. Thus, CB stem cells are amenable to treatment of a wide variety of diseases including cardiovascular, hepatic, ophthalmic, orthopaedic, neurological and endocrine diseases.

Entities:  

Mesh:

Year:  2007        PMID: 18220914     DOI: 10.2174/157488807782793790

Source DB:  PubMed          Journal:  Curr Stem Cell Res Ther        ISSN: 1574-888X            Impact factor:   3.828


  31 in total

Review 1.  Stemming vision loss with stem cells.

Authors:  Valentina Marchetti; Tim U Krohne; David F Friedlander; Martin Friedlander
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

Review 2.  Very small embryonic-like stem cells: biology and therapeutic potential for heart repair.

Authors:  Ewa K Zuba-Surma; Wojciech Wojakowski; Mariusz Z Ratajczak; Buddhadeb Dawn
Journal:  Antioxid Redox Signal       Date:  2011-05-05       Impact factor: 8.401

3.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

Review 4.  Advances in treatment and management: immunologic and cell-based regenerative therapies.

Authors:  Martin Friedlander
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-04       Impact factor: 4.799

Review 5.  Private cord blood banking: current use and clinical future.

Authors:  Peter Hollands; Catherina McCauley
Journal:  Stem Cell Rev Rep       Date:  2009-07-15       Impact factor: 5.739

6.  20-HETE regulates the angiogenic functions of human endothelial progenitor cells and contributes to angiogenesis in vivo.

Authors:  Li Chen; Rachel Ackerman; Mohamed Saleh; Katherine H Gotlinger; Michael Kessler; Lawrence G Mendelowitz; John R Falck; Ali S Arbab; A Guillermo Scicli; Michal L Schwartzman; Jing Yang; Austin M Guo
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

Review 7.  The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine.

Authors:  N Forraz; C P McGuckin
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

8.  Cell Therapy From Bench to Bedside Translation in CNS Neurorestoratology Era.

Authors:  Hongyun Huang; Lin Chen; Paul Sanberg
Journal:  Cell Med       Date:  2010-01-01

9.  Validation of reference and identity-defining genes in human mesenchymal stem cells cultured under unrelated fetal bovine serum batches for basic science and clinical application.

Authors:  Federica Banfi; Alessandra Colombini; Carlotta Perucca Orfei; Valentina Parazzi; Enrico Ragni
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

Review 10.  Cord blood stem cells: a review of potential neurological applications.

Authors:  David T Harris
Journal:  Stem Cell Rev       Date:  2008-08-05       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.